Phase 3 study of MRTX849 + Cetuximab vs. Chemo in patients with colon cancer w/KRAS G12C mutation

A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy

Disease Types: Colon

Available at: Alleghany, Blacksburg, Roanoke, Salem, Wytheville

A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy

For More Information:

https://clinicaltrials.gov/study/NCT04793958?term=A%20Randomized%20Phase%203%20Study%20of%20MRTX849%20in%20Combination%20with%20Cetuximab%20Versus%20Chemotherapy%20in%20Patients%20with%20Advanced%20Colorectal%20Cancer%20with%20KRAS%20G12C%20Mutation%20with%20Disease%20Progression%20On%20or%20After%20Standard%20First-Line%20Therapy&rank=1